X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the terms of the agreement, Aditxt will acquire Appili along with its pipeline, which includes the ATI-1701 vaccine. Currently, the vaccine is undergoing evaluation in preclinical trials for the treatment of tularemia.
Lead Product(s): ATI-1701
Therapeutic Area: Infections and Infectious Diseases Product Name: ATI-1701
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Aditxt
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 02, 2024
Details:
The funding will be used to advance the ATI-1701, potential first-in-class vaccine candidate for the prevention of infection with Francisella tularensis, program toward an IND submission.
Lead Product(s): ATI-1701
Therapeutic Area: Infections and Infectious Diseases Product Name: ATI-1701
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: USAFA
Deal Size: $14.0 million Upfront Cash: Undisclosed
Deal Type: Funding October 25, 2023
Details:
Likmez(metronidazole) is a taste-masked liquid oral reformulation of metronidazole which effectively treats Clostridium difficile infection (CDI) in children by inhibiting protein synthesis by interacting with DNA leading cell death in susceptible organisms.
Lead Product(s): Metronidazole
Therapeutic Area: Infections and Infectious Diseases Product Name: Likmez
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Saptalis pharm
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 25, 2023
Details:
ATI-1501 (metronidazole) is a taste-masked liquid oral reformulation of metronidazole which effectively treats Clostridium difficile infection (CDI) in children by inhibiting protein synthesis by interacting with DNA leading cell death in susceptible organisms.
Lead Product(s): Metronidazole
Therapeutic Area: Infections and Infectious Diseases Product Name: ATI-1501
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 24, 2023
Details:
The funding will be used to advance Appili’s Biodefense Vaccine Candidate ATI-1701 to IND. ATI-1701 is a potential first-in-class vaccine candidate for the prevention of infection with Francisella tularensis, the causative agent of tularemia and a top-priority biothreat.
Lead Product(s): ATI-1701
Therapeutic Area: Infections and Infectious Diseases Product Name: ATI-1701
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: U.S. Air Force Academy
Deal Size: $14.0 million Upfront Cash: Undisclosed
Deal Type: Funding May 08, 2023
Details:
ATI-1501 (metronidazole) is a taste-masked liquid oral reformulation of metronidazole which effectively treats Clostridium difficile infection (CDI) in children by inhibiting protein synthesis by interacting with DNA leading cell death in susceptible organisms.
Lead Product(s): Metronidazole
Therapeutic Area: Infections and Infectious Diseases Product Name: ATI-1501
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 08, 2023
Details:
ATI-1501 (metronidazole) is a taste-masked liquid oral reformulation of metronidazole which effectively treats Clostridium difficile infection (CDI) in children by inhibiting protein synthesis by interacting with DNA leading cell death in susceptible organisms.
Lead Product(s): Metronidazole
Therapeutic Area: Infections and Infectious Diseases Product Name: ATI-1501
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 13, 2023
Details:
ATI-1701 is a potential first-in-class vaccine candidate for the prevention of infection with aerosolized Francisella tularensis, a top-priority biothreat.
Lead Product(s): ATI-1701
Therapeutic Area: Infections and Infectious Diseases Product Name: ATI-1701
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: U.S. Department of Defense
Deal Size: $14.0 million Upfront Cash: Undisclosed
Deal Type: Funding November 14, 2022
Details:
Avigan/Reeqonus is a broad-spectrum antiviral in oral tablet form. It is a selective inhibitor of viral RNA-dependent RNA polymerase (RdRP) with potent antiviral activity against single-stranded RNA viruses, including coronaviruses.
Lead Product(s): Favipiravir
Therapeutic Area: Infections and Infectious Diseases Product Name: Avigan
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 14, 2022
Details:
Appili to present update on topical formulation of paromomycin, ATI-1801 already shown to be safe and effective against the disfiguring disease, cutaneous leishmaniasis, in Phase 3 study.
Lead Product(s): Paromomycin
Therapeutic Area: Infections and Infectious Diseases Product Name: ATI-1801
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 02, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
